Immunosuppression in liver transplantation (2005)

Early mythology depicts two saints in a life-and-death struggle to save a limb from a foregone fate. Saints Cosmos and Damien replaced a cancerous leg with a limb from a deceased Moor. This illustration was mere fantasy until the latter part of the previous century with the seminal surgeries performed by Dr. Joseph Murray on identical twins and, later, Dr. Starzl's pioneering orthotopic liver transplant (OLT). Immunosuppression itself has come from the dark ages to where it stands today: a careful balancing act between toxicity and rejection.1-3 This article is designed as an overview of current immunosuppression in OLT and will not delve into areas such as basic science or pipeline preview. The first attempts at whole liver grafting were carried out in 1955 with auxiliary grafts. This involved insertion of an extra liver at an ectopic location. This approach left the diseased liver intact. Early results, however, were disappointing. This early experience in the animal model and later attempts in humans led to the development of the OLT model. This was first attempted in 1963 in humans and today is the primary model for liver transplantation.4 Early immunosuppression was suboptimal at best. Corticosteroids and azathioprine were used in combination by Starzl et al. in his first 5 transplants. The majority of the Colorado series from 1963 to 1976 received corticosteroids, azathioprine, and antilymphocyte globulin. A total of 170 patients were transplanted, and approximately 50% were children. Patients were divided into 3 time-based series. Series 1 (1963-1976, 111 patients) had a 1-year survival rate of 28.8%, Series 2 (1976-1978, 30 patients) had a 1-year survival rate of 50%, and the Series 3 (1978-1979, 29 patients) had a 1-year survival rate of 34.5%. Variations on these approaches included thoracic duct drainage or cyclophosphamide, though neither produced significant advantage. The Cambridge University group reported on a series from 1968 to 1980 with a total of 93 patients, with a 1-year survival rate of 23.7%. The lower survival rate may have been due to the lower rate of pediatric patients transplanted by the Cambridge group.5, 6 This time frame has been referred to as the precyclosporine (CyA) era (Fig. 1). Timeline for the introduction of immunosuppression medications. OLT, orthotopic liver transplantation; CNIs, calcineurin inhibitors; CyA, cyclosporine; TAC, tacrolimus; IL, interleukin; MMF, mycophenolate mofetil; MPA, mycophenolic acid; ATG, antithymocyte globulin; RAP, Rapamune. The early 1970s saw the introduction of a new class of immunosuppressants, the so-called “calcineurin inhibitors” (CNIs). These compounds form the backbone of immunosuppression in liver transplantation recipients. Currently, 2 CNIs are available: CyA and tacrolimus (TAC). CyA was discovered by Jean-Francois Borel in 1973 from a soil fungus, Tolypocladium inflatum. Food and Drug Administration approval was obtained in 1983.7 CyA causes selective suppression of cell-mediated immunity via inhibition of T-cell activation. After forming a complex with its cytoplasmic receptor protein (cyclophilin), CyA binds to and inhibits the calcium and calmodulin-dependent phosphatase calcineurin (Fig. 2). It is believed that calcineurin plays a vital role in the transcriptional process by which interleukin (IL) 2 and other cytokines are activated. The production of these substances by T helper cells is a vital component of the immune response and is central to the graft rejection process. Illustration showing the activation of a T lymphocyte (via 3-signal pathway) by an antigen-presenting cell. Further detail includes the specific sites targeted by the calcineurin inhibitors (TAC and CyA) showing inhibition of IL-2 production. Monoclonal antibodies (basiliximab, daclizumab) target the IL-2 receptor, while OKT3 targets the T-cell receptor. Sirolimus, MPA, MMF, azathioprine, and FK778 interfere with the proliferative phase in the cell cycle. Novel agent FTY720 alters lymphocyte trafficking/homing patterns through modulation of cell surface adhesion receptors inducing a lymphopenic effect. Two formulations of CyA are presently available. The standard formulation (Sandimmune) was the first to come to market and requires an emulsification step prior to digestion and subsequent release of the CyA. The step is heavily dependent on food intake, biliary flow, and gastrointestinal motility and therefore subject to unpredictable bioavailability, with values ranging from 1% to 89% with a mean of 30%. The newer formulations are microemulsion preconcentrates (Neoral, Gengraf), which consist of the drug in a lipophilic solvent. These formulations produce more consistent bioavailability and are less dependent on biliary flow.8 CyA is metabolized primarily in the liver via cytochrome P450-3A pathway. Drug interactions are common (Tables 1A and 1B). Nephrotoxicity is one of the main side effects of CyA therapy. This can be both an acute and a long-term complication, inducing a post-OLT rate of renal failure up to 20%.9 Common metabolic abnormalities include hyperkalemia, hypomagnesemia, hyperlipidemia, and, to a lesser extent, hyperglycemia. Hypertension, gingival hyperplasia and hirsutism are also a common occurrence. Between 10% and 28% of patients have neurological manifestations that range from mild tremor and peripheral neuropathy to psychoses, hallucinations, motor weakness, and seizures (Table 2).10 CyA initial dosage ranges from 10 to 15 mg/kg/day divided into 2 doses. Adjustment of the oral dose is based on trough level measurement, usually within 24 hours of starting CyA. Target trough levels vary widely. Commonly used dose-targeted ranges in liver transplantation would be 250-350 ng/mL during weeks 1-2, 200-300 ng/mL during weeks 3-4, 150-250 ng/mL during weeks 5-24, and 100-200 ng/mL during weeks 25-52.11, 12 More recently, dose adjustments based on blood concentration at 2 hours after dose has been shown to more closely correlate total exposure vs. C0 monitoring (trough). One example of this would be target blood concentration levels of 850 to 1400 ng/mL at 2 hours after dose from 0 to 3 months posttransplant.13 In 1984, a soil sample containing the fungus Streptomyces tsukubaensis was discovered from near Mt. Tsukuba in Japan. Two years after this discovery, TAC was isolated.14 TAC is 100 times more potent than CyA and exerts its action by binding to FK binding protein (FKBP12). This complex then inhibits calcineurin, which is responsible for transcription of IL-2, IL-3, IL-4, IL-8, and various chemotactic factors. TAC absorption occurs in the duodenum and jejunum. Unlike CyA, TAC absorption is not influenced by presence of bile, which is advantageous in cholestatic patients or those with biliary diversion or ileus. Food reduces bioavailability, and TAC should be taken on an empty stomach. Metabolism occurs in the liver via the cytochrome P450-3A. Coadministration of medications that inhibit or induce cytochrome P450 may significantly affect blood levels of TAC (Tables 1A and 1B). Side effects are similar to CyA, including nephrotoxicity, neurotoxicity, posttransplant diabetes mellitus, and hyperkalemia.15 In general, the difference between the 2 CNIs can be summarized as follows: TAC has a higher rate of posttransplant diabetes mellitus, while CyA predisposes to more hypertension, dyslipidemia, hirsutism, and gum hyperplasia (Table 3). Initial dose guidelines for TAC range from 0.1 to 0.15 mg/kg/day orally. Dosages are modulated based on trough levels. Factors affecting adjustments are disease state, renal function, age of the patient, and other concomitant medications. Therapeutic goals for TAC early after surgery would be from 10-15 ng/mL. Multicenter trials have shown OLT patients receiving TAC-based immunosuppression compared to CyA have a lower rate of rejection within the first year, and patients infected with hepatitis C have longer graft survival.16 A large percentage of OLT programs use TAC-based regimens.17 As mentioned earlier, corticosteroids have been a mainstay since early days of liver transplant. It is by far the most heavily utilized non-calcineurin inhibitor in liver transplant. Corticosteroids exert their most critical immunosuppressive effect by blocking T-cell–derived and antigen-presenting cell-derived cytokine expression. This includes IL-1, IL-2, IL-3, and IL-6.18 Corticosteroids continue to be used in reversing acute rejection and in maintenance therapy. Side effects are numerous and include hypertension, hyperglycemia, osteoporosis, hyperlipidemia, increased risk of gastric ulcers, risk of fungal and bacterial infections, and suppression of HPA axis (Table 4). Dosing varies widely but can be summarized as follows: a bolus dose of methylprednisolone just prior to surgery, i.e., 500 to 1,000 mg, followed by rapid taper over next few weeks to minimal dose, i.e., 25-50 mg/day. The vast majority of programs will try to wean corticosteroids off within the first year except in cases of autoimmune. The percentage of patients receiving corticosteroids prior to hospital discharge decreased from 91% in 2002 to 82% in 2003. In part this can be attributed to the raising concern over negative impact of this class of medication in the recurrence of hepatitis C.17 Azathioprine was the first antimetabolite used in liver transplant but its use has since decreased dramatically over time. Azathioprine is an imidazolyl derivative of mercaptopurine and antagonizes purine metabolism. The result is an inhibition in synthesis of DNA, RNA, and proteins. Current use stands at <5% of U.S. transplant centers.17 This has been primarily due to the side effect profile, which includes significant myelosuppression and hepatotoxicity (Table 5). Typical dosage is 1 to 2 mg/kg/day. Mycophenolate mofetil (MMF, CellCept) and mycophenolic acid (MPA, Myfortic) are the most recent additions to the antimetabolite arena, with MMF approval in 1995 and MPA in 2004. MPA is a delayed-release product in contrast to MMF, which is immediately released. Both formulations inhibit the de novo purine nucleotide synthesis via abrogation of the inosine monophosphate dehydrogenase and the production of guanosine nucleotides. This action leads to a blockage of DNA replication in T and B lymphocytes that are unable to use alternate salvage pathways. Studies have shown a large variation in MMF pharmacokinetics in liver transplantation related to fluctuations in serum albumin concentrations, changes not seen in the renal transplant population. Liver dysfunction impairs MPA conjugation and prolongs MPA half-life. Furthermore, TAC has been shown to augment the bioavailability of MPA, resulting in higher exposure to MPA (Tables 6A and 6B).19 The incidence of adverse effects (nausea, gastritis abdominal pain, diarrhea, and neutropenia) requiring dose reduction or withdrawal is high, ranging from 24% to 57% (Table 5).20 The most recent data on usage shows a continuing trend upward with >50% of the U.S. transplant centers reporting use within the first year of transplant.17 Initial dosage ranges from 2-3 g daily for MMF and 720 to 1,440 mg daily for MPA, divided into 2 doses. To reiterate, dose reductions are common and in some patients removed completely, especially when combined with other myelosuppressive medications, such as sirolimus. Antibody therapy has been used as a means of delaying the introduction of maintenance therapy and/or helps facilitate the removal of an immunosuppressive agent, particularly corticosteroids. Antibody therapy can be seen as depleting or receptor modulating or both. Polyclonal antilymphocyte antibody preparations are heterologous preparations. Animals (rabbits and horses) are immunized with human T cells and thymocytes. Antisera are then collected. A purified gamma globulin fraction (ATG) is used to reduce the likelihood of serum sickness. The ATG preparations approved by the Food and Drug Administration are ATGAM (of equine origin) and Thymoglobulin (of rabbit origin). These polyclonal preparations are directed at multiple different epitopes on the T cell (CD2, CD3, CD4, CD8, CD28, and the T-cell receptor) as well as CD16 found on natural killer cells and macrophages. These antibodies cause depletion of T cells by apoptosis, antibody mediated cytolysis and internalization of the cell surface receptors. The biologic effects of the depleting antibodies are profound and last longer than the presence of heterologous antibody. Side effects can include a “first-dose” effect (cytokine release syndrome) and is related to the myriad of cytokines released by these lymphocytes upon their demise. The symptoms typically include fever, chills, tachycardia, gastrointestinal disturbances, bronchospasm, and fluctuations of blood pressure, which all can be ameliorated by pretreatment with corticosteroids, diphenhydramine, and acetaminophen.20 Usage in the United States has doubled from 3% in 2002 to 6% in 2003, primarily due to new immunosuppressive strategies as outlined later in this manuscript.17 Dosing ranges from 1.5 to 5 mg/kg as a single infusion usually over 4 to 6 hours for 3-5 days, depending on the indication. Muromonab-CD3 (OKT3) is a murine-derived antibody directed to a specific portion of T cells. It exerts its activity by binding to the CD3 antigen on the surface of T lymphocytes. This binding inactivates the adjacent T-cell receptor, which is critical for activation of T lymphocytes. The end result is a rapid fall in the number of mature lymphocytes. OKT3 was first used in liver transplantation in 1987 for prophylaxis against acute cellular rejection and later to reduce CNI exposure and treatment of steroid-resistant rejection.20 More recent data has shown a significant drop-off in favor or IL-2 receptor antibodies and polyclonal preparations.17 A cytokine-release syndrome is more frequently associated with the first dose as compared to the polyclonal antibody preparations and starts 1-3 hours following administration. Reactions can be quite severe and can range from flulike symptoms (pyrexia, chills, dyspnea, chest pain, and tightness) to severe and life-threatening shocklike reactions (pulmonary edema). These symptoms can be mitigated with the administration of a corticosteroid, diphenhydramine, and acetaminophen just prior to dose administration. Reexposure to OKT3 may result in lower efficacy due to antimurine antibodies that may form. In the early transplant period when the incidence of acute cellular rejection was as high as 71% and steroid-resistant rejection was more common, OKT3 was the mainstay in the treatment of steroid-resistant rejection with high salvage rates.21, 22 Currently, steroid-resistant rejection rates are much lower, thanks to improved immunosuppressive agents and strategies. OKT3 use today is much lower, with many centers preferring treatment regimens for acute cellular rejection to increasing TAC blood levels and then adding corticosteroid boluses if rejection is still present.17, 23 FDA approved dosage is 5 mg intravenously daily for 10 to 14 days. Dosage adjustment or drug discontinuation may be necessary if there is a reduced T-cell clearance (increase in CD3-positive T cells) or low plasma OKT3 plasma levels. Two products are currently marketed: basiliximab (Simulect) and daclizumab (Zenapax). Daclizumab is a humanized product while basiliximab shows chimeric properties. Both bind to the IL-2R α-chain, which is upregulated on the surface of activated T lymphocytes. Immunosuppression is achieved by competitive antagonism of IL-2-induced T-cell proliferation. Although the half-lives of both drugs are decreased in liver transplant patients when compared to kidney recipients, the immunosuppressive effects extend well into the third week for basiliximab and up to 10 weeks for daclizumab.20 Side effects are generally mild for both agents and comparable to placebo.24 Although neither agent is FDA approved for use in liver transplantation, usage appears to be increasing. Typical dosing for basiliximab is 20 mg given intravenously on the day of surgery, prior to engraftment. A second dose of 20 mg is given 4 days later. dosage for daclizumab is 1 mg/kg 14 days for a total of 5 doses. A number of to the daclizumab have been reported in over the few years and will be later in The following agents are used at different in liver from to is a related to with and the latter 2 are not binds to the and the response of and activation by which and in TAC and CyA inhibit the production of binds to the as TAC, it has a different of blockage of at the of and of many to the binding for as the of Early in the liver transplant was from a out of A number of liver transplant patients were given combination therapy of TAC and with targeted levels of ng/mL and 5 cellular rejection rates were with an of 23 that multiple side effects have its use early on in liver This includes serum and and oral (Table The most side effect has been the of and includes the following in liver and efficacy of as immunosuppressive therapy have not been in liver transplant patients, and therefore such use is not Drug interactions are common and can be profound (Tables and A from Colorado compared 170 liver transplantation patients to and CNIs in a corticosteroid patients had a 1-year significant difference was seen between the 2 in to this can be the of with low is in corticosteroid from the side effects of osteoporosis, hyperglycemia, hypertension, as well as the effects on recurrence of hepatitis The first was by the et al. The first group of patients received TAC, MMF and a of rabbit antithymocyte globulin rabbit 1.5 mg/kg on day and The second group received TAC, MMF, and corticosteroids with was survival in group was The rejection rate in the rabbit ATG group was vs. TAC blood levels were and all patients in the group in other group for and that percentage was significant The incidence of hepatitis C was 50% in the rabbit ATG group and 71% in the group not and recurrence of hepatitis C were not A similar daclizumab MMF and both receiving TAC a reduction in rejection in the group the adverse were the incidence of diabetes and were higher and in the was at 3 these are results, with longer are The by et al. and et al. a the incidence of renal failure after 30 to of patients renal failure within 5 years after receiving a of patients were severe renal a significantly higher percentage when compared to Both to a role of strategies have been to in this One approach has adding MMF and the dose of the calcineurin inhibitor or the calcineurin inhibitor These have produced some with up to 50% of patients showing at a in renal A number of have shown an increased risk of rejection when the CNI is with at the impact of patients with renal of CNI to patients with posttransplant were for time to is approximately 2 was at 2 and were to levels of 4 to 10 ng/mL. not and 6 to renal The of 14 patients had a in that to week still on the time to and it can be used in the early posttransplant trials are in an to these few have at calcineurin inhibitor The data from the of transplant of patients are on TAC or The of agents in where rejection has less of a negative impact on the long-term survival has some but to has been to with this medication therapy in the transplant is a that has seen a over time and still has a to Early of as a means to therapy through of immunosuppressive medications, and graft This is still The is far to a to and of these regimens helps programs to and are to patients to that their for delaying the introduction of CNIs to for renal to corticosteroid for with or hepatitis or hepatitis B for patients infected with hepatitis are for the of human DNA, new have to based on drug metabolism. the of significant in the of immunosuppressive drug with reduced rates of rejection and